Myelodysplastic syndrome transformation

1 trials MedDRA PT
1 Registered trials
0 Recruiting
1 Unique sponsors
4 Unique IMPs
1 Commercial trials
Drug classes (ATC)
L Oncology (ATC L) 1
M Musculoskeletal (ATC M) 1
V Various (ATC V) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 3 substances
BCL-2 inhibitor 1 substance
Phase I (First in Human): 1

Filter these 1 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 1 trials

Phase I (First in Human)

1 trial
  • Institut De Recherches Internationales Servier IRIS Commercial
    ALLOPURINOL; RASBURICASE; S227928; VENETOCLAX
    2024-514356-33-00 3 countries 2025 n=54
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Institut De Recherches Internationales Servier IRIS Commercial 1 Phase I (First in Human) 0
New trials by year
2025
1
← All indication landscapes